Johnson & Johnson's Steady Performance Amid Market Volatility

As of today, Johnson and Johnson's stock price is around one hundred sixty-five dollars and twelve cents per share. The trading volume has been significant, with over eight million seven hundred forty thousand shares exchanged, which is slightly above its average volume. This indicates a moderate level of interest in the stock. Recently, there have been several notable updates from analysts. Bank of America raised its price target for Johnson and Johnson from one hundred fifty-nine dollars to one hundred seventy-one dollars, reflecting a neutral stance on the stock. Other analysts have also adjusted their targets, with Royal Bank of Canada setting a target of one hundred eighty-one dollars and Morgan Stanley lowering theirs to one hundred sixty-three dollars. Overall, the stock has a moderate buy rating from analysts, with a consensus target price of approximately one hundred seventy-one dollars and thirty-three cents. Johnson and Johnson has been in the news for its recent earnings report, where it exceeded revenue expectations with twenty-two billion five hundred twenty million dollars in revenue and earnings per share of two dollars and four cents. The company has also made headlines with its pharmaceutical developments, including a positive opinion from the Committee for Medicinal Products for Human Use for its drug DARZALEX SC. In terms of market performance, Johnson and Johnson has underperformed the broader market over the past year but has shown stronger performance in recent months. Its beta is very low, indicating that the stock is less sensitive to overall market fluctuations. This stability, combined with its diverse healthcare portfolio, makes it an attractive option for investors seeking defensive positions in the market. For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.